ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of ...

Background and Expertise - The analyst has a strong background in life sciences with a PhD in Bioengineering and over 20 years of experience in the research and development of novel Cell & Gene Therapies (CGT) [2] - The analyst focuses on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging their expertise to assess the potential of novel treatments and their impact on shareholder returns [2] Disclosure and Independence - The analyst has no stock, option, or similar derivative positions in any of the companies mentioned and no plans to initiate any such positions within the next 72 hours [1] - The analyst is not receiving compensation for the article other than from Seeking Alpha and has no business relationship with any company whose stock is mentioned [1] - The analyst is associated with another Seeking Alpha contributor, "Euro Invest," but each works independently and adheres to Seeking Alpha's Shared Association Guidelines [2]

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies in synthetic biology, engineer biological systems for practical applications, including pharmaceuticals and agriculture, using genetic engineering and biotechnology techniques to design novel organisms and processes. The promise of curing genetic diseases and extending human lifespan position ...

What's going on with CRISPR Therapeutics (CRSP 0.83%)? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date.Can CRISPR Therapeutics bounce back? Some recent developments could move the needle for the gene-editing specialist down the road. Let's find out what they are and what they mean for investors.Expanded coverage for CRISPR Therapeutics' crown jewelSince November 2 ...

CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth. Plus, investors just got another big green flag to invest in its stock.Here's what you need to know.This new development augurs a bright futurePer the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the Food and Drug Administr ...

Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a drug or treatment using a breakthrough technology.Biotech companies with promising gene therapies in their portfolio/pipeline have garnered investors’ attention in 2024. Interest in this space renewed following the FDA approval of a few gene therapies toward the end of 2023.Consequently, some pharma/biotech bigwigs scurried for a lucrative catch in the space, either through licensing dea ...

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (CRSP 1.05%) first treatment last December, and its successful launch could push the stock much higher.  Investment bank analysts also expect Iovance Biotherapeutics (IOVA 0.13%) to soar in 2025.Before chasing exciting price targets, thou ...

CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases. In 2023, the company's Casgevy product for sickle cell disease became the first-ever CRISPR-based therapy approved by the Food and Drug Administration (FDA) as an important company milestone.Nevertheless, commercialization has been slow, with the market already waiting for ...

Shares of CRISPR Therapeutics AG (CRSP) have gained 0.8% over the past four weeks to close the last trading session at $51.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $81 indicates a potential upside of 58.3%.The mean estimate comprises 24 short-term price targets with a standard deviation of $34.31. While the lowest estimate of $30 indicates a 41.4% decline from the cur ...

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum. This takes time, but patient investors could score a major win by following Wood's strategy -- and by picking up a couple of her favorite stocks. Over the past several weeks, Wood has added to one of her key positions, a stock that's lost about ...